The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity

Fu, Ke; Wang, Cheng; Ma, Cheng; Zhou, Honglin; Li, Yunxia

doi:10.3389/fphar.2021.771459

Cited by 24 publications

(13 citation statements)

References 342 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an alternative medical practice with a history of thousands of years. TCM has the advantages of low cost and high safety and modulates various biological activities, and it has been suggested to be effective in many liver conditions [ 49 ]. Currently, it is in phase III, and results are expected at the end of the year.…”

Section: Discussionmentioning

confidence: 99%

Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed

Balzano

2023

Neurochem Res

View full text Add to dashboard Cite

Hepatic encephalopathy (HE) is a potentially reversible neurocognitive syndrome that occurs in patients with acute or chronic liver disease. Currently, most of the therapies for HE aim to reduce ammonia production or increase its elimination. To date, only two agents have been approved as treatments for HE: lactulose and rifaximin. Many other drugs have also been used, but data to support their use are limited, preliminary or lacking. The aim of this review is to provide an overview and discussion of the current development of treatments for HE. Data from ongoing clinical trials in HE were obtained from the ClinicalTrials.gov website, and a breakdown analysis of studies that were active on August 19th, 2022, was performed. Seventeen registered and ongoing clinical trials for therapeutics targeting HE were identified. More than 75% of these agents are in phase II (41.2%) or in phase III (34.7%). Among them, there are many old acquaintances in the field, such as lactulose and rifaximin, some new entries such as fecal microbiota transplantation and equine anti-thymocyte globulin, an immunosuppressive agent, but also some therapies borrowed from other conditions, such as rifamycin SV MMX and nitazoxanide, two antimicrobial agents FDA approved for the treatment of some types of diarrheas or VE303 and RBX7455, two microbiome restoration therapies, currently used as treatment of high-risk Clostridioides difficile infections. If working, some of these drugs could soon be used as valid alternatives to current therapies when ineffective or be approved as novel therapeutic approaches to improve the quality of life of HE patients. Supplementary Information The online version contains supplementary material available at 10.1007/s11064-023-03916-w.

show abstract

Section: Discussionmentioning

confidence: 99%

Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed

Balzano

2023

Neurochem Res

View full text Add to dashboard Cite

show abstract

“…Traditional Chinese medicine (TCM) plays an important role in the prevention and treatment of ALD through the synergistic effects of its various components as many TCM formulas had been reported to be effective in protecting against both various discomfort feelings by alcohol binge drinking and alcohol-induced liver injury by chronic alcohol taken [ 13 , 16 , 28 ]. Among them, Bao-Gan-Xing-Jiu-Wan (BGXJW), a clinical experience-based Chinese herbal preparation (pills), exhibit excellent clinical outcomes as they can effectively prevent ALD and relieve drunkenness.…”

Section: Introductionmentioning

confidence: 99%

A clinical experience-based Chinese herbal formula improves ethanol-induced drunken behavior and hepatic steatohepatitis in mice models

Gao

Liu

et al. 2023

Chin Med

View full text Add to dashboard Cite

Background Bao-Gan-Xing-Jiu-Wan (BGXJW) is a clinical experience-based Chinese herbal formula. Its efficacy, pharmacological safety, targeted function, process quality, and other aspects have met the evaluation standards and the latest requirements of preparations. It could prevent and alleviate the symptoms of drunkenness and alcoholic liver injury clinically. The present work aims to elucidate whether BGXJW could protect against drunkenness and alcoholic liver disease in mice and explore the associated mechanism. Material and methods We used acute-on-chronic (NIAAA) mice model to induce alcoholic steatosis, and alcohol binge-drinking model to reappear the drunk condition. BGXJW at indicated doses were administered by oral gavage respectively to analyze its effects on alcoholic liver injury and the associated molecular mechanisms. Results BGXJW had no cardiac, hepatic, renal, or intestinal toxicity in mice. Alcoholic liver injury and steatosis in the NIAAA mode were effectively prevented by BGXJW treatment. BGXJW increased the expression of alcohol metabolizing enzymes ADH, CYP2E1, and ALDH2 to enhance alcohol metabolism, inhibited steatosis through regulating lipid metabolism, counteracted alcohol-induced upregulation of lipid synthesis related proteins SREBP1, FASN, and SCD1, meanwhile it enhanced fatty acids β-oxidation related proteins PPAR-α and CPT1A. Alcohol taken enhanced pro-inflammatory TNF-α, IL-6 and down-regulated the anti-inflammatory IL-10 expression in the liver, which were also reversed by BGXJW administration. Moreover, BGXJW significantly decreased the blood ethanol concentration and alleviated drunkenness in the alcohol binge-drinking mice model. Conclusions BGXJW could effectively relieve drunkenness and prevent alcoholic liver disease by regulating lipid metabolism, inflammatory response, and alcohol metabolism. Graphical Abstract

show abstract

“…Traditional Chinese medicine (TCM) has unique advantages in the clinical treatment of liver injury due to its characteristics of multitarget and multiapproach ( Fu et al, 2021 ). The pharmacokinetic study of TCM is helpful to elucidate the in vivo process characteristics of the active ingredients of TCM and clarify the pharmacodynamic material basis of them ( Fu et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Comparative Pharmacokinetics of Three Bioactive Diterpenoids of Rabdosia serra Extract in Normal and Con A-Induced Liver Injury Rats Using UPLC-MS/MS

et al. 2022

View full text Add to dashboard Cite

Rabdosia serra (Maxim.) Hara (R. serra), one of the source plants of “Xihuangcao”, has been widely used as a Chinese folk herb with the concomitant function of both medicine and foodstuff for the prevention and treatment of liver disease. Diterpenoids were considered as the major bioactive components in R. serra, responsible for their effect on hepatoprotection in previous phytochemical and pharmacological studies, while few comparative pharmacokinetic studies have been conducted under the physiological and pathological conditions. To reveal the difference in the pharmacokinetics process of R. serra extract (RSE) in normal and Con A-induced liver injury rats, a rapid ultra-high-pressure liquid chromatography–tandem mass spectrometry method (total running time: 5 min) was established to simultaneously determine three bioactive diterpenoids (enmein, epinodosin, and isodocarpin) in rat plasma. The results showed significant differences in the pharmacokinetic properties of three analytes between the physiological and pathological states. Compared with normal rats, the AUC of the three analytes was remarkably higher in liver injury rats, while the Tmax, T1/2, and MRT were shortened. It indicated that RSE has higher exposure and quicker elimination in liver injury rats than that in normal rats. Our results suggested that the pharmacokinetics of hepatoprotective medications was affected by liver injury, which prospected to provide essential information for guiding the healthcare and clinical application of R. serra in pathological states.

show abstract

The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity

Cited by 24 publications

References 342 publications

Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed

Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed

A clinical experience-based Chinese herbal formula improves ethanol-induced drunken behavior and hepatic steatohepatitis in mice models

Comparative Pharmacokinetics of Three Bioactive Diterpenoids of Rabdosia serra Extract in Normal and Con A-Induced Liver Injury Rats Using UPLC-MS/MS

Contact Info

Product

Resources

About